Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

Plain-language summary

This study observes changes in DRD2 gene expression from nasal swab samples in patients with restless legs syndrome (RLS) on prolonged dopamine agonist treatment. People with a clinical diagnosis of RLS who are on ongoing dopamine agonist therapy and can give consent may take part. It is a non-phase study that is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

HBC Immunology Inc

Start date

7/1/2025

Estimated completion

2/27/2026

Countries

United States

Related genes

Locations

• San Francisco, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Able to provide Informed Consent
* Clinical diagnosis of Restless Legs Syndrome (RLS)
* On-going Treatment with a dopamine agonist

Exclusion Criteria:

\* Use of any medication that might affect nasal epithelial cell collection with a nasal swab